Bladder cancer treatment to lower the chance of it coming back
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new way to give a chemotherapy drug during bladder surgery to help stop the cancer from returning. It is for people with a type of bladder cancer that has not spread into the muscle.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a bladder tumor that will be removed with a scope during surgery.
- After surgery, the tumor is confirmed to be a certain type of bladder cancer (non-muscle-invasive) with medium or high risk of coming back.
- You are willing to join the study and sign a consent form.
- You do not have certain bladder or urinary problems, a history of pelvic radiation, or other serious health conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This study tests a more targeted way to treat low-grade bladder cancer using chemotherapy placed directly into the bladder. Before treatment, your cancer cells are grown in the lab to see which drug works best for you.
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (gemcitabine) given directly into the bladder after surgery to remove high-risk bladder tumors. The goal is to reduce the chance of the cancer coming back.
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.